8-K: Jaguar Health Converts Preferred Stock to Common, Warrants

Jaguar Health, Inc. completed two privately negotiated exchange agreements with Iliad Research and Trading, L.P., converting Series M Preferred Stock into common stock and pre-funded warrants.

Summary

• Jaguar Health, Inc. (the Company) entered into two privately negotiated exchange agreements with Iliad Research and Trading, L.P. (Iliad) on December 9, 2025, and December 11, 2025.
• The First Exchange Agreement involved the issuance of 400,000 shares of common stock and a pre-funded common stock purchase warrant to acquire 1,304,545 shares of common stock to Iliad, in exchange for 75 shares of Series M Perpetual Preferred Stock held by Iliad.
• The Second Exchange Agreement involved the issuance of 40,000 shares of common stock and a pre-funded common stock purchase warrant to acquire 304,827 shares of common stock to Iliad, in exchange for 16 shares of Series M Preferred Stock held by Iliad.
• A total of 91 shares of Series M Preferred Stock were cancelled and retired as a result of these transactions.
• In total, 440,000 shares of common stock were issued, and pre-funded warrants to purchase an aggregate of 1,609,372 shares of common stock were granted.
• Each pre-funded warrant is immediately exercisable at an exercise price of $0.001 per share and includes a beneficial ownership limitation of 9.99%.

Sentiment

Score: 4

Explanation: While the conversion of preferred stock simplifies the capital structure, the significant dilution from the issuance of common stock and warrants is a notable negative for common shareholders, leading to a moderately negative sentiment.

Positives

• The conversion of Series M Preferred Stock simplifies the company's capital structure by reducing the number of outstanding preferred shares.
• Cancellation of preferred stock eliminates potential future preferred dividend obligations associated with those shares.

Negatives

• The issuance of 440,000 shares of common stock and pre-funded warrants to purchase an additional 1,609,372 shares will result in significant dilution for existing common shareholders.
• The exercise of the pre-funded warrants at a nominal price of $0.001 per share could further increase the outstanding common stock count, potentially exerting downward pressure on the stock price.

Risks

• Significant dilution of existing common stock due to the issuance of new common shares and the potential exercise of pre-funded warrants.
• Potential downward pressure on the company's stock price as a result of increased share count and the availability of additional shares from warrant exercises.

Future Outlook

NA

Industry Context

This transaction represents a capital structure adjustment, a common practice for companies seeking to simplify their equity base or manage obligations related to preferred stock. It does not directly reflect broader industry trends but is an internal financial management decision.

Related Party Transactions

• The company engaged in privately negotiated exchange agreements with Iliad Research and Trading, L.P., a significant holder of the company's Series M Preferred Stock.

Stakeholder Impact

• Common shareholders will experience dilution due to the issuance of new common stock and the potential exercise of pre-funded warrants, which could impact per-share metrics and stock price.
• Preferred shareholders (Iliad) have converted their preferred equity into common equity and warrants, potentially gaining liquidity and upside exposure to common stock.

Next Steps

• Potential exercise of the pre-funded common stock purchase warrants by Iliad Research and Trading, L.P.

Key Dates

Recommendation

The conversion of preferred stock into common stock and warrants, while simplifying the capital structure, introduces significant dilution for existing common shareholders. This dilution could exert downward pressure on the stock price. However, the elimination of preferred stock obligations is a positive. Given these offsetting factors, a 'hold' recommendation is appropriate, advising investors to monitor the impact of dilution and future operational performance.

Keywords

Jaguar Health, JAGX, Iliad Research and Trading, Series M Preferred Stock, Common Stock, Pre-Funded Warrants, Equity Conversion, Capital Structure, Dilution, SEC Filing